Trade Names:
Synonyms:
Status: Approved (2015)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L01XC22
UNII: 2BT4C47RUI

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Epidermal growth factor receptor erbB1 inhibitor DailyMed
Primary Target
epidermal growth factor receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Neoplasm Metastasis 1 D009362 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
15.66
General disorders and administration site conditions
13.86
Respiratory, thoracic and mediastinal disorders
11.45
Injury, poisoning and procedural complications
10.24
Cardiac disorders
9.64
Infections and infestations
7.83
Investigations
5.42
Vascular disorders
5.42
Metabolism and nutrition disorders
4.22
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.22
Gastrointestinal disorders
3.61
Immune system disorders
3.01
Nervous system disorders
3.01

Cross References

Resources Reference
CAS NUMBER 906805-06-9
ChEMBL CHEMBL1743047
FDA SRS 2BT4C47RUI
Guide to Pharmacology 8090